SGCA Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant SGCA.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND

Application
| WB, E |
|---|---|
| Primary Accession | Q16586 |
| Other Accession | NM_000023 |
| Reactivity | Human |
| Host | mouse |
| Clonality | Monoclonal |
| Isotype | IgG2b Kappa |
| Clone Names | 3C4 |
| Calculated MW | 42875 Da |
| Gene ID | 6442 |
|---|---|
| Other Names | Alpha-sarcoglycan, Alpha-SG, 50 kDa dystrophin-associated glycoprotein, 50DAG, Adhalin, Dystroglycan-2, SGCA, ADL, DAG2 |
| Target/Specificity | SGCA (NP_000014.1, 26 a.a. ~ 133 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Dilution | WB~~1:500~1000 E~~N/A |
| Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
| Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
| Precautions | SGCA Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a component of the dystrophin-glycoprotein complex (DGC), which is critical to the stability of muscle fiber membranes and to the linking of the actin cytoskeleton to the extracellular matrix. Its expression is thought to be restricted to striated muscle. Mutations in this gene result in type 2D autosomal recessive limb-girdle muscular dystrophy. Multiple transcript variants encoding different isoforms have been found for this gene.
References
Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Fernandez K, et al. Am J Pathol, 2010 Jan. PMID 20019182.Sarcoglycanopathies: can muscle immunoanalysis predict the genotype? Klinge L, et al. Neuromuscul Disord, 2008 Dec. PMID 18996010.Identification of two E-boxes that negatively modulate the activity of MyoD on the alpha-sarcoglycan core promoter. Delgado-Olgu?n P, et al. Biochim Biophys Acta, 2008 Jan. PMID 18078839.Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. Rafii MS, et al. J Cell Physiol, 2006 Nov. PMID 16883602.Sarcoglycanopathies and the risk of undetected deletion alleles in diagnosis. White SJ, et al. Hum Mutat, 2005 Jul. PMID 15954112.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.





Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.




